These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9845094)

  • 1. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo.
    Papadopoulou MV; Ji M; Bloomer WD
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):775-9. PubMed ID: 9845094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
    Papadopoulou MV; Ji M; Bloomer WD
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):160-8. PubMed ID: 11561782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo.
    Papadopoulou MV; Ji X; Bloomer WD
    J Exp Ther Oncol; 2006; 5(4):261-72. PubMed ID: 17024967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts.
    Papadopoulou MV; Ji M; Bloomer WD; Hollingshead MG
    J Exp Ther Oncol; 2002; 2(5):298-305. PubMed ID: 12416033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamine.
    Papadopoulou MV; Ji M; Bloomer WD
    Oncol Res; 2002; 13(1):47-54. PubMed ID: 12201674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic interaction between cyclophosphamide or paclitaxel and the bioreductive compound NLCPQ-1, in vivo.
    Papadopoulou MV; Ji M; Bloomer WD
    Oncol Res; 2003; 13(12):561-6. PubMed ID: 12899246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine.
    Papadopoulou MV; Ji M; Ji X; Bloomer WD
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):291-8. PubMed ID: 12357303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
    Papadopoulou MV; Ji M; Rao MK; Bloomer WD
    Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents.
    Papadopoulou MV; Bloomer WD
    In Vivo; 2007; 21(2):175-80. PubMed ID: 17436565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
    Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
    Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN
    J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): a novel DNA-affinic bioreductive agent as chemosensitizer. I.
    Papadopoulou MV; Ji M; Rao MK; Bloomer WD
    Oncol Res; 1997; 9(5):249-57. PubMed ID: 9306432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. THNLA-1: a DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo.
    Papadopoulou MV; Ji M; Bloomer WD
    In Vivo; 1996; 10(1):49-57. PubMed ID: 8726811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-dependent retinal toxicity of NLCQ-1 (NSC 709257) in BALB/c mice. Comparison with tirapazamine.
    Papadopoulou MV; Ji M; Bloomer WD
    Basic Clin Pharmacol Toxicol; 2011 Jun; 108(6):396-9. PubMed ID: 21205223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms involved in the potentiation of paclitaxel or 5-fU by the hypoxic cytotoxin NLCQ-1 (NSC 709257) in vitro.
    Papadopoulou MV; Ji X; Bloomer WD
    Anticancer Res; 2005; 25(3B):2161-70. PubMed ID: 16158959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin.
    Papadopoulou MV; Ji M; Rao MK; Bloomer WD
    Oncol Res; 2000; 12(4):185-92. PubMed ID: 11341468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents.
    Teicher BA; Herman TS; Hopkins RE; Menon K
    J Cancer Res Clin Oncol; 1992; 118(2):123-8. PubMed ID: 1735732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigational new drug-directed, 5-day repeat dose toxicity study of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1, NSC 709257) administered with or without Taxol in Sprague-Dawley rats.
    Papadopoulou MV; Bloomer WD; Torti VR; Page JG
    Basic Clin Pharmacol Toxicol; 2010 Jun; 106(6):497-504. PubMed ID: 20074267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug.
    Papadopoulou MV; Bloomer WD
    Clin Cancer Res; 2003 Nov; 9(15):5714-20. PubMed ID: 14654556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.